Loading fund overlap…
11 of 180 unique stocks in common · Jaccard: 6.1%
A weighted portfolio overlap of 9.58% indicates a low overlap (mostly different holdings). This means that out of every ₹100 you invest across these two schemes, approximately ₹9.58 is allocated to the exact same companies at the same relative proportions. The schemes share 11 common holdings.
The largest overlapping asset in their portfolios is Cipla, which commands a weight of 5.28% in Back to Index and 2.89% in HDFC Flexi Cap Fund. Holding both schemes increases your concentration in Cipla rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Back | in HDFC |
|---|---|---|
| CiplaPharmaceuticals & Biotechnology | 5.28% | 2.89% |
| Max Healthcare InstituteHealthcare Services | 5.23% | 1.38% |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | 5.90% | 1.18% |
| LupinPharmaceuticals & Biotechnology | 3.97% | 0.74% |
| Piramal PharmaPharmaceuticals & Biotechnology | 0.71% | 1.53% |
| Dr. Lal Path LabsHealthcare Services | 0.75% | 0.66% |
| Aster DM HealthcareHealthcare Services | 1.32% | 0.64% |
| Apollo Hospitals EnterpriseHealthcare Services | 5.55% | 0.58% |
| Metropolis HealthcareHealthcare Services | 0.36% | 0.35% |
| Anthem BiosciencesPharmaceuticals & Biotechnology | 0.33% | 0.57% |
| Neuland LaboratoriesPharmaceuticals & Biotechnology | 0.92% | 0.12% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on May 2026). Equity holdings only, ISIN-verified. Not investment advice.